期刊文献+

酸响应聚合物-铂共轭纳米颗粒给药载体的抑癌作用 被引量:2

Tumor Inhibition of Acid-Responsive Polymer-Cisplatin Conjugate Nanoparticles Drug Delivery System
下载PDF
导出
摘要 目的合成酸响应聚合物-铂共轭的纳米体系,验证该结合体作为给药载体对癌症细胞的抑制作用。方法合成酸响应聚合物-铂共轭的纳米药物载体,在酸性环境中模拟药物的释放,用噻唑蓝(MTT)法检测其对细胞活性的影响。结果聚合物-铂共轭纳米颗粒显示出可控的铂负载率,良好的酸响应药物释放动力学,在pH=7.4时,释放量很少,而在pH=5.0或6.0时药物释放明显。与游离顺铂相比,对于卵巢癌细胞显示出较高的体外细胞毒性,包裹在聚合物-铂共轭纳米颗粒中相当于7μmol·L-1游离顺铂的药物量,可以达到与50μmol·L-1游离顺铂药物相当的细胞毒性效果。结论聚合物-铂共轭纳米颗粒体系为酸响应药物输送体系,可以显著提高药物的生物利用度,有望在癌细胞内快速释放高剂量的化疗药物对癌细胞起到抑制作用,改善负载药物的治疗效果。 Objective To synthesize polymer-cisplatin conjugate nanoparticles for acid-responsive drug delivery, and verify the inhibitory effect of the nano-system on cancer cells. Methods Acid-responsive polymer-cisplatin conjugate nano-drug carrier was synthesized to simulate the drug release under an acidic environment. Cell viability was examined by MTT assay. Results The polymer-cisplatin nanoparticles exhibited well-controlled cisplatin loading rate, and excellent acid-responsive drug release kinetics. At pH 7. 4, little drug was released. At pH 5. 0 or 6. 0,the drug release was significant. Compared with free cisplatin,cisplatin in the conjugate nanoparticles showed higher cytotoxicity against ovarian cancer cells in vitro. An equivalent dose of 7 μmol·L^-1 cisplatin loaded in the conjugate nanoparticles exhibited same cytotoxicity as 50μmol·L^-1 free cisplatin.Conclusion Polymer-cisplatin conjugate is an acid-responsive drug delivery system that greatly improves the bioavailability of cisplatin to tumor cells. It is expected to play a better tumor inhibition effect by quickly releasing a high dose of chemotherapy drug inside tumor cells.
作者 梁涛
出处 《医药导报》 CAS 北大核心 2014年第9期1132-1136,共5页 Herald of Medicine
关键词 顺铂 纳米颗粒 聚合物 酸响应 药物递送 药物释放 细胞毒性 Cisplatin Nanoparticles,polymer Acid-responsive Drug delivery Drug release Cytotoxicity
  • 相关文献

参考文献16

  • 1GALANSKI M,ARION V B,JAKUPEC M A. Recent devel-opments in the field of tumor-inhibiting metal complexes[J]. Curr Pharm Des,2003,9(10):2078-2089.
  • 2PASINI A,ZUNINO F. New cisplatin analogues-on the wayto better antitumor agents[J]. Angew Chem Int Ed Engl,1987,26(5):615-624.
  • 3WONG E,GIANDOMENICO C M. Current status of platin-um-based antitumor drugs[J]. Chem Rev,1999,9(10):2451-2466.
  • 4ANDREWS P A,WUNG W E,HOWELL S B. A highper-formance liquid chromatographic assay with improvedselectivity for cisplatin and active platinum(II) complexesin plasma of rat[J]. Anal Biochem,1984,143(1):46-56.
  • 5BORCH R F,PLEASANTS M E. Inhibition of cis-platinumnephrotoxicity by diethyl dithiocarbamate rescue in a ratmodel[J]. Proc Natl Acad Sci USA,1979,76(24):6611-6614.
  • 6DOLMAN R C,DEACON G B,HAMBLEY T W. Studies ofthe binding of a series of platinum ( IV) complexes toplasma proteins[J]. J Inorg Biochem,2002,88(2):260-267.
  • 7ANG W H,KHALAILA I,ALLARDYCE C S. Rational des-ign of platinum(IV) compounds to overcome glutathione-s-transferase mediated drug resistance[J]. J Am Chem Soc,2005,127(10):1382-1383.
  • 8DHAR S,GU F X,FAROKHZAD O C. Targeted delivery ofcisplatin to prostate cancer cells by aptamer functionalizedPt(IV) prodrug-PLGA-PEG nanoparticles[J]. Proc NatlAcad Sci USA,2008,105(24):17356-17361.
  • 9OHYA Y,OUE H,NAGATOMI K. Design of macromolecu-lar prodrug of cisplatin using dextran with branchedgalactose units as targeting moieties to hepatoma cells[J].Biomacromolecules,2001,2(7):927-933.
  • 10ANG W H,PILET S,SCOPELLITI R. Synthesis and char-acterization of platinum ( IV ) anticancer drugs withfunctionalized aromatic carboxylate ligands:influence of theligands on drug efflucacies and uptake[J]. J Med Chem,2005,48(24):8060-8069.

同被引文献12

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部